"The debate revealed conflicting evidence about C1q's role - some studies show it drives synaptic loss while others suggest it facilitates protective amyloid clearance. This fundamental mechanistic uncertainty undermines therapeutic targeting strategies. Source: Debate session sess_SDA-2026-04-01-gap-v2-691b42f1 (Analysis: SDA-2026-04-01-gap-v2-691b42f1)"
Multi-agent debate between AI personas, each bringing a distinct perspective to evaluate the research question.
Generates novel, bold hypotheses by connecting ideas across disciplines
Description: C1q mediates distinct functions depending on subcellular localization—synaptic C1q drives complement-dependent synapse loss, while microglial/meningeal C1q facilitates Aβ clearance. A locally delivered C1q inhibitor (e.g., small molecule or
...Description: C1q mediates distinct functions depending on subcellular localization—synaptic C1q drives complement-dependent synapse loss, while microglial/meningeal C1q facilitates Aβ clearance. A locally delivered C1q inhibitor (e.g., small molecule or peptide) targeting synaptic compartments could block pathogenic pruning while preserving peripheral immune clearance functions.
Target Gene/Protein: C1q (classical complement pathway initiation)
Supporting Evidence:
Description: C1q possesses distinct binding interfaces for Aβ (protective) versus neuronal membranes (pathogenic). A rationally designed peptide or small molecule targeting the neuronal membrane-binding domain of C1q would preserve Aβ opsonization while blocking synaptic complement deposition and subsequent C3-mediated pruning.
Target Gene/Protein: C1q (specifically the collagen-like domain interface with neuronal membranes)
Supporting Evidence:
Description: C1q and TREM2 operate in opposing microglial states—C1q marks synapses for elimination while TREM2 promotes homeostatic phagocytosis. Combined therapy using C1q inhibitors (to block synapse loss) with TREM2 agonists (to enhance Aβ clearance) could synergistically reduce pathology while preserving physiological functions. This addresses the compensatory/pathogenic dichotomy by targeting both pathways simultaneously.
Target Gene/Protein: C1q (inhibition) + TREM2 (activation)
Supporting Evidence:
Description: C1q elevation is compensatory in early AD (enhancing Aβ clearance) but becomes pathogenic in established disease (mediating synaptic loss through chronic complement activation). A cyclical treatment regimen—C1q inhibition during moderate-to-severe disease, with drug holidays during early/prodromal stages—would preserve protective clearance when most needed while blocking late-stage synaptic damage.
Target Gene/Protein: C1q (temporally modulated inhibition)
Supporting Evidence:
Description: C4, not C1q, may be the critical initiator of pathological synapse loss in AD, while C1q is primarily protective for Aβ clearance. Genetic or pharmacological targeting of C4 (upstream of C3 activation but downstream of immune complex formation) would block pathogenic complement amplification at synapses while preserving C1q's direct opsonization functions for amyloid clearance.
Target Gene/Protein: C4 (classical/lectin pathway amplification)
Supporting Evidence:
Description: Neuronal activity suppresses C1q expression through GABAergic signaling and activity-dependent gene regulation. Environmental enrichment, cognitive stimulation, or GABAergic compounds (e.g., benzodiazepine-sparing agents) could maintain physiological C1q levels, preventing the pathological overexpression that drives synaptic loss while preserving clearance functions.
Target Gene/Protein: C1q (regulated by neuronal activity/gene expression)
Supporting Evidence:
Description: The pathogenic effects of C1q in AD are mediated specifically through C3a receptor (C3aR) signaling on microglia, not through C3b-mediated opsonization. Selective C3aR antagonists would block the synaptic elimination signal while preserving C1q's direct role in opsonizing Aβ for phagocytic clearance. This represents a downstream "effector" approach that sidesteps the upstream C1q dichotomy.
Target Gene/Protein: C3aR (C3a receptor, downstream of C1q-C3 axis)
Supporting Evidence:
Challenges assumptions, identifies weaknesses, and provides counter-evidence
Before evaluating individual hypotheses, I must identify a core limitation affecting all seven proposals: the field has not definitively established that C1q elevation in human AD is primarily pathogenic rather than a consequence of, or response to, other disease drivers. The cited PM
...Before evaluating individual hypotheses, I must identify a core limitation affecting all seven proposals: the field has not definitively established that C1q elevation in human AD is primarily pathogenic rather than a consequence of, or response to, other disease drivers. The cited PMIDs largely derive from mouse models where complement components are genetically manipulated—translational relevance to sporadic human AD remains contested.
Compartmentalization assumption lacks mechanistic rigor. The hypothesis posits that synaptic versus microglial C1q functions are molecularly distinct based on localization, but C1q is a secreted protein. It does not exist in "synaptic" versus "microglial" pools with different primary structures. The functional outcomes differ based on what C1q is binding to, not where the C1q molecule resides. This reframing matters for drug development: a small molecule cannot selectively inhibit C1q at synapses while preserving it at microglia if the same protein surface mediates both interactions.
Evidence for separable immune defense is indirect. The claim that synaptic C1q inhibition preserves "complement-dependent microbial defense" assumes these are mechanistically separable pathways. However, systemically administered C1q inhibitors would affect all complement activity, including surveillance of the blood-brain barrier and meningeal immune populations that interact with peripheral immune cells.
C1q has pleiotropic protective functions beyond Aβ clearance. C1q inhibits amyloid fibril formation and toxicity in vitro through direct binding, suggesting neuroprotective functions independent of microglial clearance (PMID: 12451177). Blocking C1q in any compartment risks losing this intrinsic protective activity.
Developmental synapse pruning is physiological. C1q-mediated synapse elimination occurs during normal brain development (PMID: 27518564). The hypothesis assumes pathological overactivation in AD, but evidence for a quantitative rather than qualitative difference in C1q function is limited. If the same mechanism underlies both development and pathology, spatial targeting may be infeasible.
The apparent dichotomy between synaptic loss and Aβ clearance may reflect temporal dynamics rather than spatial segregation. Early C1q elevation may reflect beneficial immune surveillance; later synaptic damage may result from chronic exposure and microglial priming rather than C1q per se.
Key experiment: Generate conditional C1q knockout mice where C1q is deleted specifically in microglia versus neurons versus astrocytes. If spatial segregation theory holds, astrocyte-specific C1q deletion should preserve synaptic function while impairing Aβ clearance. Current evidence suggests astrocyte-derived C1q is a major source (PMID: 32109516), but functional dissection has not been performed.
Quantitative measurement: Use protein crosslinking and live-cell imaging to directly measure whether the same C1q molecule can simultaneously bind Aβ and neuronal membranes, or whether these represent mutually exclusive states.
C1q structural studies do not support clean interface separation. While cryo-EM structures reveal distinct binding surfaces (PMID: 30042826), the globular heads of C1q utilize overlapping or allosterically linked surfaces for multiple ligands. The assumption that distinct residues mediate Aβ versus membrane binding requires high-resolution mapping that remains incomplete.
The therapeutic molecule would require extraordinary specificity. Designing a compound that blocks C1q-neuronal membrane interaction without affecting C1q-C1q trimerization, C1q-IgM complex formation, or C1q-Aβ binding (which also involves the globular domain) is technically daunting. The therapeutic window would be narrow.
C1q binds Aβ through its collagen-like domain, not the globular heads. The structural literature on C1q-Aβ binding (PMID: 11734555) indicates interactions involve distinct regions from classical immune complex recognition. The hypothesis incorrectly assigns Aβ binding to the globular heads based on this citation.
C1q's pathogenic synapse elimination requires downstream C3, not direct neuronal binding. If the mechanism is complement cascade activation rather than direct C1q cytotoxicity (as stated in the hypothesis), then blocking the C1q-membrane interface would not address the core pathological mechanism—the complement amplification cascade would still proceed through alternative pathway activation.
The pathological signal may derive from C1q binding to apoptotic neurons (which expose phosphatidylserine) rather than healthy synaptic membranes. This would suggest targeting C1q-phosphatidylserine interactions rather than a generic "neuronal membrane" interface.
Key experiment: Solve the co-crystal structure of C1q bound to both Aβ42 oligomers and neuronal-derived membrane preparations. If the interfaces are truly distinct, these structures should reveal separable binding domains. If they overlap, the hypothesis fails.
Competition assays: Test whether Aβ binding to C1q blocks subsequent C1q-mediated complement activation on neuronal membranes. If these are competitive, selective inhibition is theoretically possible; if non-competitive, spatial targeting fails.
TREM2 agonists are not clinically available. While the scientific rationale is compelling, this hypothesis depends on a therapeutic modality that does not yet exist for human use. The confidence score should reflect this translational gap.
The TREM2-C1q relationship is bidirectional, not simply opposing. TREM2 deficiency does not simply remove a brake on C1q-mediated pathology; it also impairs homeostatic microglial function broadly. The net effect of combined manipulation is difficult to predict from current evidence.
Pharmacokinetic challenges are severe. Two drugs, two dosing regimens, two safety profiles—this combination would require extraordinary safety data to advance clinically.
TREM2 and C1q may operate in different microglial states rather than opposition. Single-cell studies reveal multiple microglial states in AD (PMID: 30664763), with TREM2-high and complement-high populations potentially coexisting rather than mutually exclusive. The "opposing states" framing may be an oversimplification.
TREM2 activation may not always be beneficial. Recent evidence suggests that excessive TREM2 signaling can lead to pathological microglial clustering around plaques with limited functional benefit (PMID: 33674489). Timing and degree of activation matter.
Rather than simultaneous targeting, sequential therapy may be more appropriate: C1q inhibition in early disease to prevent synaptic loss, followed by TREM2 activation to enhance clearance once pathology is established.
Key experiment: Test the dual therapy in the TREM2 knockout background using C1q inhibitors. If TREM2 deficiency fully rescues pathology, C1q inhibition adds nothing—falsifying the independence assumption.
Single-cell transcriptomics: Profile microglia during dual therapy to determine whether C1q inhibition and TREM2 activation target the same or different cellular populations.
No validated biomarker for determining therapeutic windows exists. The hypothesis requires identifying when C1q transitions from compensatory to pathogenic, but CSF or plasma C1q levels have not been validated as decision-making biomarkers.
The "drug holiday" concept is clinically risky. Stopping treatment to preserve potential compensatory functions creates a treatment-free interval during which pathology may progress. The risk-benefit calculation requires Phase III data that do not exist.
The temporal transition point is uncharacterized. The hypothesis assumes a discrete shift from compensatory to pathogenic function, but C1q may be both simultaneously throughout disease.
C1q elevation is already present in preclinical/early AD. If C1q were compensatory in early disease, one might expect lower C1q in resistant individuals. Instead, C1q elevation appears to be a universal feature of AD pathology, suggesting it is either a consequence of pathology rather than a modifier, or that the compensatory/pathogenic dichotomy is incorrect.
Complement activation products are elevated across all AD stages. C3a, C4a, and downstream markers remain elevated (PMID: 30664763), suggesting that even if C1q has stage-dependent roles, the downstream cascade does not respect the same timing.
C1q is an epiphenomenon, not a disease driver. The correlation between C1q elevation and disease progression may reflect glial activation as a response to neurodegeneration, with no causal role in synaptic loss.
Key experiment: Longitudinal measurement of C1q alongside synaptic markers (e.g., neurofilament light chain) and Aβ clearance rates in the same individuals. If C1q elevation predicts subsequent synaptic loss independent of Aβ burden, it supports a causal role; if synaptic loss occurs despite C1q elevation, the compensatory interpretation fails.
Mendelian randomization: Test whether genetic variants affecting C1q expression levels influence AD risk. If C1q elevation is pathogenic, genetic variants increasing C1q should associate with increased AD risk.
C4's role in AD is less studied than C1q. The hypothesis cites PMID: 27929084, but this reference primarily concerns C1q and C3 rather than C4. The specific evidence for C4 deposition being sufficient for synaptic elimination in AD models is limited.
C4b deposition is downstream of C1q activation. While C4 is upstream of C3, it is still downstream of the proposed therapeutic target. If C1q is protective (Aβ clearance), then C4 inhibition would not preserve this function.
The "C4 deficiency prevents synaptic loss" claim is from model systems. The PMID: 28822697 reference concerns an anterior eye compartment model, not brain synapses. Direct extrapolation is unwarranted.
C1q can activate C3 directly without C4. Alternative pathway amplification and MASP-mediated C3 activation can bypass C4. Inhibiting C4 would not fully block complement-mediated synapse elimination.
C4 has roles in adaptive immunity that would be impaired. C4 deficiency is associated with lupus-like autoimmunity (PMID: 2849061). Unlike C1q inhibition, C4 inhibition carries risks of systemic immune dysregulation.
Targeting C3 directly (e.g., with pegcetacoplan) is already in clinical trials for AD (NCT05132582). This bypasses the upstream complexity while addressing the final common pathway of complement-mediated synapse loss.
Key experiment: Measure C4a and C4b deposition in AD brain tissue across disease stages. If C4 activation correlates with synaptic loss but not with Aβ burden, it supports selective C4 targeting. If C1q correlates more strongly, C1q remains the better target.
C4 knockout in AD models: Direct testing in APP/PS1 or 5xFAD mice crossed with C4-deficient animals would provide definitive evidence.
Effect sizes are modest. The cited evidence for physical activity and cognitive enrichment reducing complement activation is largely correlative, with small effect sizes in animal models.
The neuronal activity-C1q relationship is indirect. C1q is primarily expressed by microglia and astrocytes, not neurons. The hypothesis relies on activity-dependent suppression of glial C1q production, which is a multi-step cascade.
GABAergic compounds have narrow therapeutic windows. Benzodiazepines and related agents have significant side effect profiles that would limit chronic use in elderly AD populations.
Cognitive stimulation may work through entirely different mechanisms. Physical activity reduces neuroinflammation through multiple pathways (BDNF, IL-10, microglial polarization) without necessarily engaging C1q specifically (PMID: 28986280).
The IL-33 pathway is one of several suppressive mechanisms. Relying on astrocyte-derived IL-33 (PMID: 32109516) ignores other regulatory pathways that may compensate if this one is pharmacologically manipulated.
Non-pharmacological approaches may be more practical. Rather than developing C1q-targeting drugs, optimizing lifestyle factors (exercise, cognitive engagement, social interaction) may achieve the desired effect without drug development risks.
Key experiment: Perform a head-to-head comparison of voluntary exercise versus direct C1q inhibition in AD models, measuring both Aβ clearance and synaptic preservation. If exercise works through non-C1q mechanisms, the hypothesis is falsified.
Activity-dependent gene profiling: Identify the transcription factors and signaling cascades that suppress C1q during neuronal activity, then test whether targeting these upstream regulators reproduces the exercise effect.
C3aR has broader microglial functions. C3aR signaling modulates multiple microglial behaviors beyond synapse elimination, including chemotaxis, cytokine production, and metabolic state. Blocking C3aR would have systemic effects on microglial biology.
Downstream of C1q does not mean independent of upstream. The claim that C3aR blockade "sidesteps the upstream C1q dichotomy" is incorrect—C3a is generated from C3, which can be activated through multiple pathways (classical, lectin, alternative), not only C1q.
C3aR antagonism would not preserve C1q-Aβ clearance. If C1q directly opsonizes Aβ for microglial phagocytosis, this function is preserved. However, if microglial phagocytosis requires C3aR signaling for activation, blocking C3aR would impair clearance.
C3aR deficiency enhances some inflammatory responses. Loss of C3aR signaling can paradoxically increase inflammation in certain contexts (PMID: 25970247). The assumption that blocking C3aR is uniformly beneficial requires caution.
The C1q-Aβ-C1qR pathway is poorly defined. The claim that C1q-Aβ complexes are phagocytosed through C1q receptors independent of C3aR (PMID: 10925283) cites 1999 work that has not been substantially extended. The phagocytic pathway for C1q-opsonized material remains unclear.
C5aR blockade (already tested in Phase II trials for AD) may achieve similar effects with more clinical development history.
Key experiment: Compare C1q knockout, C3aR knockout, and C3aR+C1q double knockout mice in AD models. If C1q knockout and C3aR knockout have identical phenotypes, downstream targeting is equivalent. If they differ, the upstream dichotomy matters.
Mechanistic dissection: Use C3aR antagonists versus C1q inhibitors in the same model, measuring Aβ clearance rates (e.g., via longitudinal PET imaging) alongside synaptic markers. Divergent effects would indicate that C1q has C3aR-independent functions.
Hypothesis 3 (Dual-Target C1q + TREM2) has the strongest foundation, though it remains limited by translational gaps. The scientific rationale—that opposing microglial states require coordinated modulation—is mechanistically sound and consistent with emerging single-cell data.
Hypothesis 2 rests on incorrect structural assumptions (Aβ binding to globular heads rather than collagen-like domain) and fails to recognize that downstream complement activation would proceed through alternative pathways.
Hypothesis 7 is the most immediately translatable, as C3aR antagonists exist and have been tested in Phase II trials. The theoretical limitations do not preclude empirical testing.
Assesses druggability, clinical feasibility, and commercial viability
Before addressing individual hypotheses, a core issue must be acknowledged: none of these seven hypotheses have been subjected to human genetic validation. Common variants in C1QA, C1QB, or C1QC have not reached genome-wide signi
...Before addressing individual hypotheses, a core issue must be acknowledged: none of these seven hypotheses have been subjected to human genetic validation. Common variants in C1QA, C1QB, or C1QC have not reached genome-wide significance in AD GWAS (currently dominated by APOE, TREM2, PLCG2, ABI3, and clusterin loci). This absence is not neutral—it suggests that C1q elevation may be an epiphenomenon of glial activation rather than a disease driver. The hypotheses collectively treat C1q elevation as causally pathogenic, but the field lacks the genetic causal inference that anchors targets like TREM2 (R47H variant; PMID: 29288425).
The therapeutic hypotheses also share a critical pharmacokinetic obstacle: C1q is a 410 kDa hexameric protein whose inhibitors must cross the blood-brain barrier. Every proposed intervention faces this barrier, and most fail.
The fundamental problem: C1q is a secreted protein synthesized primarily by microglia and astrocytes, with additional contributions from neurons and endothelial cells. It does not exist in discrete "synaptic" versus "microglial" pools with different primary structures. The functional outcomes differ based on what C1q is binding to, not where the molecule happens to be when a drug reaches it. A systemically administered small molecule cannot selectively inhibit C1q at a subset of synapses while preserving its function at microglia throughout the brain.
Existing chemical matter:
Annexon is the clear leader. The ANX005 AD program represents the primary competitive asset in this space. No other company has advanced a selective C1q inhibitor past Phase 1 for neurodegeneration.
Structural biology problem: The hypothesis incorrectly assigns Aβ binding to the globular heads of C1q. The literature (PMID: 11734555) indicates that C1q's collagen-like domain and globular heads both contribute to Aβ binding, with the actual interface being more complex than assumed. More recent cryo-EM studies (PMID: 30042826) show that C1q utilizes a large surface area for ligand interactions, and structural studies suggest significant allosteric coupling between domains. Designing a selective inhibitor that blocks binding to neuronal membranes without affecting Aβ opsonization or C1q-C1q trimerization is a high bar.
Chemical matter available:
The hypothesis claims C1q triggers synapse elimination "via downstream C3 activation, not direct cytotoxicity," then proposes blocking the C1q-membrane interface as the therapeutic solution. These assertions are contradictory. If synapse elimination requires downstream complement cascade activation rather than direct C1q binding, then blocking the C1q-membrane interface does not prevent C3-mediated pruning—the cascade can still be initiated through alternative pathway activation (which is robustly activated by Aβ deposits themselves) or through lectin pathway activation via MBL-associated serine proteases (MASPs). The therapeutic rationale collapses.
This hypothesis has the strongest scientific foundation because it addresses the mechanistic dichotomy directly rather than trying to separate one function from another. The concept of coordinated microglial state modulation is consistent with single-cell transcriptomics showing that complement-high and TREM2-high microglia represent distinct states with different functional outputs.
Existing chemical matter:
For C1q inhibition:
Annexon (C1q) and Alector/AbbVie (TREM2) represent the primary dual candidates. No company has disclosed a co-development agreement for combined C1q inhibition + TREM2 activation, and the pharmacokinetic, safety, and regulatory hurdles for a combination therapy in AD are formidable.
Combination therapy challenges:
Revised Confidence: 0.55 (down from 0.70). Scientific rationale remains strongest, but the AL002 Phase 2 failure and combinatorial development challenges are substantial.
The core problem: no validated biomarker exists to determine the therapeutic window. The hypothesis requires distinguishing when C1q is "compensatory" versus "pathogenic." Current measures include:
Existing approaches:
C4 is a critical node in adaptive immunity. C4b deposition is essential for immune complex clearance, and C4 deficiency is associated with lupus-like autoimmunity (SLE shows strong association with C4 null alleles; PMID: 2849061). Unlike C1q inhibition, which preserves lectin and alternative pathway activation, C4 inhibition would disrupt both classical and lectin pathways more completely.
Existing chemical matter:
This is not a drug development hypothesis—it is a lifestyle intervention hypothesis dressed in molecular language. The evidence for exercise and cognitive enrichment reducing complement activation is correlative with modest effect sizes in animal models. The claim that these effects are mediated specifically through neuronal activity-dependent C1q regulation has not been definitively demonstrated.
Existing chemical matter:
C3aR is a GPCR, which is highly druggable. Small molecule antagonists are achievable, and existing tool compounds provide good starting points.
Existing chemical matter:
Tool compounds:
The hypothesis claims C3aR blockade "sidesteps the upstream C1q dichotomy" by targeting the "effector" arm. This is mechanistically incorrect. C3a is generated from C3 cleavage, which can occur through C1q-dependent (classical pathway), MASP-dependent (lectin pathway), or alternative pathway activation. Aβ deposits robustly activate complement through the alternative pathway independently of C1q. Blocking C3aR would not preserve C1q-dependent Aβ clearance if that clearance depends on any complement-mediated opsonization pathway.
Furthermore, if microglial phagocytosis of Aβ requires C3aR signaling for full activation, C3aR blockade would paradoxically impair clearance while blocking synapse elimination.
| Target | Druggability Class | BBB Challenge | Clinical Stage Asset |
|--------|-------------------|---------------|----------------------|
| C1q (H1-4) | Protein (mAb) | High (mAb penetration) | ANX005 (Phase 1b/2 completed) |
| C1q binding interface (H2) | Protein-protein interface | Very High | None |
| C1q + TREM2 (H3) | Dual biologics | Very High | ANX005 + AL002 (separate programs) |
| C4 (H5) | Protein (small molecule possible) | Moderate | None |
| Neuronal activity (H6) | Indirect/GPCR | Low-Medium | No viable pharmacological approach |
| C3aR (H7) | GPCR | Moderate | Tool compounds only, no AD program |
Hypothesis 7 (C3aR) has the best druggability profile (GPCR target with known tool compounds) but lacks any active development program for AD. Hypothesis 1 (C1q broadly) has the most clinical development activity (ANX005), despite the compartmental targeting limitation.
The most defensible development pathway is actually a hybrid: Use ANX005 (anti-C1q) as the primary intervention while developing a biomarker strategy to identify the optimal therapeutic window. This combines elements of H1 and H4.
Annexon (ANX005) ─── C1q inhibition ─── Phase 1b/2 completed
Alector/AbbVie (AL002) ─── TREM2 agonism ─── Phase 2 completed (failed?)
Apellis (Pegcetacoplan) ─── C3 inhibition ─── Phase 2 planned
Neurocrine/Pepgen (C1-INH) ─── Classical pathway ─── Phase 1/2
Roche/Biogen ─── Anti-C5 (Eculizumab biosimilar?) ─── Early exploration
The ANX005 trial results will be the pivotal data for the entire C1q-in-AD hypothesis space.
| Hypothesis | Development Stage | Estimated Cost | Timeline to Phase 2 |
|------------|------------------|----------------|---------------------|
| H1 (C1q spatial) | Phase 1b/2 | ~$50-80M already invested | Readout 2024-2025 |
| H3 (C1q + TREM2) | Pre-clinical combination | ~$200-300M (two programs) | 2028-2030 (if AL002 resuscitated) |
| H4 (Stage-dependent) | Biomarker development needed | ~$100M + biomarker program | 2030+ (dependent on biomarker) |
| H5 (C4) | Preclinical | ~$150M | 2030+ |
| H6 (Activity) | Lifestyle/non-pharmacological | ~$10M (study costs) | Already addressable |
| H7 (C3aR) | No active AD program | ~$100-150M to Phase 1 | 2028-2030 |
The most defensible therapeutic hypothesis is a modified H3 (dual targeting) combined with the temporal insight of H4. The field should await the ANX005 Phase 2 readout and AL002 post-mortem analyses before committing to combination strategies. If ANX005 shows biomarker evidence of target engagement (complement activation reduction) but insufficient clinical efficacy, the hypothesis should shift toward downstream targeting (C3, C3aR) rather than C1q itself.
The most immediately actionable recommendation: Fund a C3aR antagonist AD program, using the existing tool compound series as starting points for medicinal chemistry optimization for CNS penetration. C3aR blockade is more druggable than C1q targeting and addresses the final common pathway of complement-mediated synapse elimination without the systemic complement activation risk of upstream classical pathway blockade.
The fundamental translational gap is not chemical matter (we have tool compounds for all targets) but rather human genetic validation, CNS penetration strategy, and therapeutic window identification. These must be addressed before any hypothesis advances to Phase 3.
Following multi-persona debate and rigorous evaluation across 10 dimensions, these hypotheses emerged as the most promising therapeutic approaches.
⚠️ No Hypotheses Generated
This analysis did not produce scored hypotheses. It may be incomplete or in-progress.
No knowledge graph edges recorded
Analysis ID: SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1
Generated by SciDEX autonomous research agent